Ibandronate

Identification

Name

Ibandronate

Accession Number

DB00710  (APRD00231, DB04635)

Type

Small Molecule

Groups

Approved, Investigational

Description

Ibandronate is a nitrogen-containing bisphosphonate in the same class as alendronate and risedronate. Ibandronate inhibits osteoclast-mediated bone resorption. All of the bisphosphonates prevent the breakdown of bone by bone cells called osteoclasts. In persons who are at high risk for osteoporosis, bisphosphonates not only result in increased amounts of bone and bone strength, they also reduce the risk of hip fractures and other bone fractures.

Structure

3D

Download

MOLSDF3D-SDFPDBSMILESInChI

Similar Structures

Structure for DB00710 (Ibandronate)

×

Close

Synonyms

• Ibandronic Acid

External IDs

R484

Product Ingredients

Ingredient	UNII	CAS	InChI Key
Ibandronate sodium	23Y0B94E49	138926-19-9	LXLBEOAZMZAZND-UHFFFAOYSA-M

Product Images

Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Bondronat	Liquid	1 mg	Intravenous	Hoffmann La Roche	2004-05-31	2006-05-17
Boniva	Tablet, film coated	150 mg/1	Oral	Physicians Total Care, Inc.	2005-06-02	Not applicable
Boniva	Injection, solution	3 mg/3mL	Intravenous	Genentech, Inc.	2011-06-01	Not applicable
Boniva	Tablet, film coated	150 mg/1	Oral	Genentech, Inc.	2002-07-15	Not applicable
Bonviva	Injection, solution	3 mg	Intravenous	Atnahs Pharma Uk Limited	2004-02-23	Not applicable
Bonviva	Tablet, film coated	150 mg	Oral	Atnahs Pharma Uk Limited	2004-02-23	Not applicable
Bonviva	Injection, solution	3 mg	Intravenous	Atnahs Pharma Uk Limited	2004-02-23	Not applicable
Bonviva	Tablet, film coated	150 mg	Oral	Atnahs Pharma Uk Limited	2004-02-23	Not applicable

Generic Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Iasibon	Injection, solution, concentrate	6 mg	Intravenous	Pharmathen S.A.	2011-01-21	Not applicable
Iasibon	Tablet, film coated	50 mg	Oral	Pharmathen S.A.	2011-01-21	Not applicable
Iasibon	Tablet, film coated	50 mg	Oral	Pharmathen S.A.	2011-01-21	Not applicable
Iasibon	Injection, solution, concentrate	6 mg	Intravenous	Pharmathen S.A.	2011-01-21	Not applicable
Iasibon	Injection, solution, concentrate	2 mg	Intravenous	Pharmathen S.A.	2011-01-21	Not applicable
Iasibon	Tablet, film coated	50 mg	Oral	Pharmathen S.A.	2011-01-21	Not applicable
Iasibon	Tablet, film coated	50 mg	Oral	Pharmathen S.A.	2011-01-21	Not applicable
Iasibon	Injection, solution, concentrate	6 mg	Intravenous	Pharmathen S.A.	2011-01-21	Not applicable
Iasibon	Injection, solution, concentrate	1 mg	Intravenous	Pharmathen S.A.	2011-01-21	Not applicable
Iasibon	Tablet, film coated	50 mg	Oral	Pharmathen S.A.	2011-01-21	Not applicable

Unapproved/Other Products

Name	Ingredients	Dosage	Route	Labeller	Marketing Start	Marketing End
Bondenza	Ibandronate (150 mg)	Tablet, film coated	Oral	Roche Registration Limited	2004-02-23	2013-05-13
Bondenza	Ibandronate (3 mg)	Injection, solution	Intravenous	Roche Registration Limited	2004-02-23	2013-05-13
Bondenza	Ibandronate (150 mg)	Tablet, film coated	Oral	Roche Registration Limited	2004-02-23	2013-05-13
Bondenza	Ibandronate (3 mg)	Injection, solution	Intravenous	Roche Registration Limited	2004-02-23	2013-05-13

International/Other Brands

ADRONiL / Bondronat / Bonviva

Categories

• Bisphosphonates
• Bone Density Conservation Agents
• Bone Resorption
• Drugs Affecting Bone Structure and Mineralization
• Drugs for Treatment of Bone Diseases
• Musculo-Skeletal System
• Organophosphonates
• Organophosphorus Compounds
• Potential QTc-Prolonging Agents
• QTc Prolonging Agents

UNII

UMD7G2653W

CAS number

114084-78-5

Weight

Average: 319.2289
Monoisotopic: 319.094975119

Chemical Formula

C₉H₂₃NO₇P₂

InChI Key

MPBVHIBUJCELCL-UHFFFAOYSA-N

InChI

InChI=1S/C9H23NO7P2/c1-3-4-5-7-10(2)8-6-9(11,18(12,13)14)19(15,16)17/h11H,3-8H2,1-2H3,(H2,12,13,14)(H2,15,16,17)

IUPAC Name

{1-hydroxy-3-[methyl(pentyl)amino]-1-phosphonopropyl}phosphonic acid

SMILES

CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O

Pharmacology

Indication

For the treatment and prevention of osteoporosis in postmenopausal women.

Associated Conditions

• Bone Metastases
• Hypercalcemia of Malignancy
• Bone destruction

Pharmacodynamics

Ibandronate is a nitrogen-containing bisphosphonate in the same class as alendronate and risedronate. Ibandronate inhibits osteoclast-mediated bone resorption. All of the bisphosphonates prevent the breakdown of bone by bone cells called osteoclasts. In persons who are at high risk for osteoporosis, bisphosphonates not only result in increased amounts of bone and bone strength, they also reduce the risk of hip fractures and other bone fractures.

Mechanism of action

The action of ibandronate on bone tissue is based partly on its affinity for hydroxyapatite, which is part of the mineral matrix of bone. Nitrogen-containing bisphosphonates (such as pamidronate, alendronate, risedronate, ibandronate and zoledronate) appear to act as analogues of isoprenoid diphosphate lipids, thereby inhibiting farnesyl pyrophosphate (FPP) synthase, an enzyme in the mevalonate pathway. Inhibition of this enzyme in osteoclasts prevents the biosynthesis of isoprenoid lipids (FPP and GGPP) that are essential for the post-translational farnesylation and geranylgeranylation of small GTPase signalling proteins. This activity inhibits osteoclast activity and reduces bone resorption and turnover. In postmenopausal women, it reduces the elevated rate of bone turnover, leading to, on average, a net gain in bone mass.

Target	Actions	Organism
AFarnesyl pyrophosphate synthase	inhibitor	Human
AHydroxylapatite	antagonist	Human

Absorption

Poorly absorbed (mean bioavailability following a 2.5 mg oral dose is about 0.6% compared to intravenous dosing). Absorption is impaired by any kind of food or drink other than plain water.

Volume of distribution

• 90 L

Protein binding

90.9 to 99.5% over an ibandronate concentration range of 2 to 10 ng/mL

Metabolism

No evidence of ibandronate being metabolized in humans.

Route of elimination

Ibandronate is eliminated by renal excretion. Unabsorbed ibandronate is eliminated unchanged in the feces.

Half life

10-60 hours

Clearance

• 84 to 160 mL/min [IV administration]

Toxicity

LD₅₀ = 811 mg/kg (rat, oral), side effects include bronchitis, pneumonia and urinary tract infections.

Affected organisms

• Humans and other mammals

Pathways

Pathway	Category
Ibandronate Action Pathway	Drug action
Ibandronate Action Pathway	Drug action

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

Drug	Interaction	Drug group
Abexinostat	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Abexinostat.	Investigational
Aceclofenac	The risk or severity of gastrointestinal bleeding can be increased when Aceclofenac is combined with Ibandronate.	Approved, Investigational
Acemetacin	The risk or severity of gastrointestinal bleeding can be increased when Acemetacin is combined with Ibandronate.	Approved, Experimental, Investigational
Aceprometazine	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Aceprometazine.	Approved
Acetylsalicylic acid	The risk or severity of gastrointestinal bleeding can be increased when Acetylsalicylic acid is combined with Ibandronate.	Approved, Vet Approved
Acrivastine	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Acrivastine.	Approved
Alcaftadine	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Alcaftadine.	Approved
Alclofenac	The risk or severity of gastrointestinal bleeding can be increased when Alclofenac is combined with Ibandronate.	Approved, Withdrawn
Alendronic acid	The risk or severity of hypocalcemia can be increased when Ibandronate is combined with Alendronic acid.	Approved
Alfuzosin	The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Ibandronate.	Approved, Investigational
Alimemazine	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Alimemazine.	Approved, Vet Approved
Almasilate	The serum concentration of Ibandronate can be decreased when it is combined with Almasilate.	Approved, Experimental
Alminoprofen	The risk or severity of gastrointestinal bleeding can be increased when Alminoprofen is combined with Ibandronate.	Experimental
Aloglutamol	The serum concentration of Ibandronate can be decreased when it is combined with Aloglutamol.	Approved
Aluminium	The serum concentration of Ibandronate can be decreased when it is combined with Aluminium.	Approved, Investigational
Aluminium acetoacetate	The serum concentration of Ibandronate can be decreased when it is combined with Aluminium acetoacetate.	Experimental
Aluminium clofibrate	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ibandronate is combined with Aluminium clofibrate.	Experimental
Aluminium glycinate	The serum concentration of Ibandronate can be decreased when it is combined with Aluminium glycinate.	Experimental
Aluminium phosphate	The serum concentration of Ibandronate can be decreased when it is combined with Aluminium phosphate.	Approved, Investigational
Aluminum hydroxide	The serum concentration of Ibandronate can be decreased when it is combined with Aluminum hydroxide.	Approved, Investigational
Amantadine	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Amantadine.	Approved
Amifampridine	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Amifampridine.	Approved
Amikacin	The risk or severity of nephrotoxicity and hypocalcemia can be increased when Amikacin is combined with Ibandronate.	Approved, Investigational, Vet Approved
Aminophenazone	The risk or severity of gastrointestinal bleeding can be increased when Aminophenazone is combined with Ibandronate.	Approved, Withdrawn
Amiodarone	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Amiodarone.	Approved, Investigational
Amitriptyline	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Amitriptyline.	Approved
Amodiaquine	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Amodiaquine.	Approved, Investigational
Amoxapine	The risk or severity of QTc prolongation can be increased when Amoxapine is combined with Ibandronate.	Approved
Amphotericin B	The risk or severity of nephrotoxicity and hypocalcemia can be increased when Amphotericin B is combined with Ibandronate.	Approved, Investigational
Anagrelide	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Anagrelide.	Approved
Anecortave	The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Anecortave is combined with Ibandronate.	Investigational
anecortave acetate	The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when anecortave acetate is combined with Ibandronate.	Investigational
Antazoline	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Antazoline.	Approved
Antipyrine	The risk or severity of gastrointestinal bleeding can be increased when Antipyrine is combined with Ibandronate.	Approved, Investigational
Antrafenine	The risk or severity of gastrointestinal bleeding can be increased when Antrafenine is combined with Ibandronate.	Approved
Apomorphine	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Apomorphine.	Approved, Investigational
Apramycin	The risk or severity of nephrotoxicity and hypocalcemia can be increased when Apramycin is combined with Ibandronate.	Experimental, Vet Approved
Arbekacin	The risk or severity of nephrotoxicity and hypocalcemia can be increased when Arbekacin is combined with Ibandronate.	Approved, Investigational
Arformoterol	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Arformoterol.	Approved, Investigational
Aripiprazole	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Aripiprazole.	Approved, Investigational
Aripiprazole lauroxil	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Aripiprazole lauroxil.	Approved, Investigational
Arsenic trioxide	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Arsenic trioxide.	Approved, Investigational
Artemether	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Artemether.	Approved
Asenapine	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Asenapine.	Approved
Astemizole	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Astemizole.	Approved, Withdrawn
Atazanavir	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Atazanavir.	Approved, Investigational
Atomoxetine	The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Ibandronate.	Approved
Atorvastatin	The risk or severity of myopathy and rhabdomyolysis can be increased when Ibandronate is combined with Atorvastatin.	Approved
Azapropazone	The risk or severity of gastrointestinal bleeding can be increased when Azapropazone is combined with Ibandronate.	Withdrawn
Azatadine	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Azatadine.	Approved
Azelastine	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Azelastine.	Approved
Azithromycin	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Azithromycin.	Approved
Azosemide	The risk or severity of hypocalcemia can be increased when Azosemide is combined with Ibandronate.	Investigational
Bacitracin	The risk or severity of nephrotoxicity and hypocalcemia can be increased when Bacitracin is combined with Ibandronate.	Approved, Vet Approved
Balsalazide	The risk or severity of gastrointestinal bleeding can be increased when Balsalazide is combined with Ibandronate.	Approved, Investigational
Bedaquiline	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Bedaquiline.	Approved
Bekanamycin	The risk or severity of nephrotoxicity and hypocalcemia can be increased when Bekanamycin is combined with Ibandronate.	Experimental
Bendazac	The risk or severity of gastrointestinal bleeding can be increased when Bendazac is combined with Ibandronate.	Experimental
Benorilate	The risk or severity of gastrointestinal bleeding can be increased when Benorilate is combined with Ibandronate.	Experimental
Benoxaprofen	The risk or severity of gastrointestinal bleeding can be increased when Benoxaprofen is combined with Ibandronate.	Withdrawn
Benzatropine	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Benzatropine.	Approved
Benzydamine	The risk or severity of gastrointestinal bleeding can be increased when Benzydamine is combined with Ibandronate.	Approved
Bepridil	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Bepridil.	Approved, Withdrawn
Besifloxacin	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Besifloxacin.	Approved
Bevacizumab	The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Bevacizumab is combined with Ibandronate.	Approved, Investigational
Bezafibrate	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ibandronate is combined with Bezafibrate.	Approved, Investigational
Bilastine	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Bilastine.	Approved, Investigational
Bismuth subnitrate	The serum concentration of Ibandronate can be decreased when it is combined with Bismuth subnitrate.	Approved
Bortezomib	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Ibandronate.	Approved, Investigational
Bromfenac	The risk or severity of gastrointestinal bleeding can be increased when Bromfenac is combined with Ibandronate.	Approved
Brompheniramine	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Brompheniramine.	Approved
Buclizine	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Buclizine.	Approved
Bufexamac	The risk or severity of gastrointestinal bleeding can be increased when Bufexamac is combined with Ibandronate.	Approved, Experimental
Bumadizone	The risk or severity of gastrointestinal bleeding can be increased when Bumadizone is combined with Ibandronate.	Experimental
Bumetanide	The risk or severity of hypocalcemia can be increased when Bumetanide is combined with Ibandronate.	Approved
Buserelin	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Buserelin.	Approved, Investigational
Butriptyline	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Butriptyline.	Approved
Calcitonin porcine	The risk or severity of hypocalcemia can be increased when Calcitonin porcine is combined with Ibandronate.	Experimental
Calcium Acetate	The serum concentration of Ibandronate can be decreased when it is combined with Calcium Acetate.	Approved, Investigational
Calcium Carbonate	The serum concentration of Ibandronate can be decreased when it is combined with Calcium Carbonate.	Approved, Investigational
Calcium Chloride	The serum concentration of Ibandronate can be decreased when it is combined with Calcium Chloride.	Approved
Calcium Citrate	The serum concentration of Ibandronate can be decreased when it is combined with Calcium Citrate.	Approved
Calcium glubionate	The serum concentration of Ibandronate can be decreased when it is combined with Calcium glubionate.	Approved
Calcium Gluceptate	The serum concentration of Ibandronate can be decreased when it is combined with Calcium Gluceptate.	Approved
Calcium gluconate	The serum concentration of Ibandronate can be decreased when it is combined with Calcium gluconate.	Approved, Vet Approved
Calcium lactate	The serum concentration of Ibandronate can be decreased when it is combined with Calcium lactate.	Approved, Investigational, Vet Approved
Calcium lactate gluconate	The serum concentration of Ibandronate can be decreased when it is combined with Calcium lactate gluconate.	Experimental
Calcium levulinate	The serum concentration of Ibandronate can be decreased when it is combined with Calcium levulinate.	Approved, Experimental
Calcium pangamate	The serum concentration of Ibandronate can be decreased when it is combined with Calcium pangamate.	Experimental
Calcium Phosphate	The serum concentration of Ibandronate can be decreased when it is combined with Calcium Phosphate.	Approved
Calcium silicate	The serum concentration of Ibandronate can be decreased when it is combined with Calcium silicate.	Experimental
Capreomycin	The risk or severity of nephrotoxicity and hypocalcemia can be increased when Capreomycin is combined with Ibandronate.	Approved
Carbaspirin calcium	The risk or severity of gastrointestinal bleeding can be increased when Carbaspirin calcium is combined with Ibandronate.	Experimental, Investigational
Carbinoxamine	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Carbinoxamine.	Approved
Carboplatin	The risk or severity of nephrotoxicity and hypocalcemia can be increased when Carboplatin is combined with Ibandronate.	Approved
Carprofen	The risk or severity of gastrointestinal bleeding can be increased when Carprofen is combined with Ibandronate.	Approved, Vet Approved, Withdrawn
Cefacetrile	The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefacetrile is combined with Ibandronate.	Approved
Cefaclor	The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefaclor is combined with Ibandronate.	Approved
Cefadroxil	The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefadroxil is combined with Ibandronate.	Approved, Vet Approved, Withdrawn
Cefalotin	The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefalotin is combined with Ibandronate.	Approved, Investigational, Vet Approved
Cefamandole	The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefamandole is combined with Ibandronate.	Approved, Investigational
Cefapirin	The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefapirin is combined with Ibandronate.	Approved, Vet Approved
Cefatrizine	The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefatrizine is combined with Ibandronate.	Experimental
Cefazedone	The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefazedone is combined with Ibandronate.	Experimental
Cefazolin	The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefazolin is combined with Ibandronate.	Approved
Cefbuperazone	The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefbuperazone is combined with Ibandronate.	Experimental
Cefcapene	The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefcapene is combined with Ibandronate.	Experimental
Cefditoren	The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefditoren is combined with Ibandronate.	Approved, Investigational
Cefepime	The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefepime is combined with Ibandronate.	Approved, Investigational
Cefetamet	The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefetamet is combined with Ibandronate.	Experimental
Cefmenoxime	The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefmenoxime is combined with Ibandronate.	Approved
Cefmetazole	The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefmetazole is combined with Ibandronate.	Approved, Investigational
Cefminox	The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefminox is combined with Ibandronate.	Approved
Cefodizime	The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefodizime is combined with Ibandronate.	Experimental
Cefonicid	The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefonicid is combined with Ibandronate.	Approved, Investigational
Cefoperazone	The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefoperazone is combined with Ibandronate.	Approved, Investigational
Ceforanide	The risk or severity of nephrotoxicity and hypocalcemia can be increased when Ceforanide is combined with Ibandronate.	Approved
Cefotaxime	The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefotaxime is combined with Ibandronate.	Approved
Cefotetan	The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefotetan is combined with Ibandronate.	Approved
Cefotiam	The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefotiam is combined with Ibandronate.	Approved, Investigational
Cefoxitin	The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefoxitin is combined with Ibandronate.	Approved
Cefozopran	The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefozopran is combined with Ibandronate.	Experimental
Cefpiramide	The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefpiramide is combined with Ibandronate.	Approved
Cefpirome	The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefpirome is combined with Ibandronate.	Approved
Cefpodoxime	The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefpodoxime is combined with Ibandronate.	Approved, Vet Approved
Cefprozil	The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefprozil is combined with Ibandronate.	Approved
Cefradine	The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefradine is combined with Ibandronate.	Approved
Cefroxadine	The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefroxadine is combined with Ibandronate.	Withdrawn
Cefsulodin	The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefsulodin is combined with Ibandronate.	Experimental
Ceftaroline fosamil	The risk or severity of nephrotoxicity and hypocalcemia can be increased when Ceftaroline fosamil is combined with Ibandronate.	Approved, Investigational
Ceftazidime	The risk or severity of nephrotoxicity and hypocalcemia can be increased when Ceftazidime is combined with Ibandronate.	Approved
Ceftezole	The risk or severity of nephrotoxicity and hypocalcemia can be increased when Ceftezole is combined with Ibandronate.	Experimental
Ceftibuten	The risk or severity of nephrotoxicity and hypocalcemia can be increased when Ceftibuten is combined with Ibandronate.	Approved, Investigational
Ceftizoxime	The risk or severity of nephrotoxicity and hypocalcemia can be increased when Ceftizoxime is combined with Ibandronate.	Approved, Investigational
Ceftobiprole	The risk or severity of nephrotoxicity and hypocalcemia can be increased when Ceftobiprole is combined with Ibandronate.	Approved, Investigational
Ceftriaxone	The risk or severity of nephrotoxicity and hypocalcemia can be increased when Ceftriaxone is combined with Ibandronate.	Approved
Cefuroxime	The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefuroxime is combined with Ibandronate.	Approved
Celecoxib	The risk or severity of gastrointestinal bleeding can be increased when Celecoxib is combined with Ibandronate.	Approved, Investigational
Cephalexin	The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cephalexin is combined with Ibandronate.	Approved, Investigational, Vet Approved
Cephaloglycin	The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cephaloglycin is combined with Ibandronate.	Approved
Cephaloridine	The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cephaloridine is combined with Ibandronate.	Approved, Withdrawn
Cephalothin Group	The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cephalothin Group is combined with Ibandronate.	Experimental
Ceritinib	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Ceritinib.	Approved
Cerivastatin	The risk or severity of myopathy and rhabdomyolysis can be increased when Ibandronate is combined with Cerivastatin.	Approved, Withdrawn
Cetirizine	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Cetirizine.	Approved
Chlorcyclizine	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Chlorcyclizine.	Approved
Chloroquine	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Chloroquine.	Approved, Investigational, Vet Approved
Chlorphenamine	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Chlorphenamine.	Approved
Chlorpromazine	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Chlorpromazine.	Approved, Investigational, Vet Approved
Chlorprothixene	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Chlorprothixene.	Approved, Investigational, Withdrawn
Choline magnesium trisalicylate	The risk or severity of gastrointestinal bleeding can be increased when Choline magnesium trisalicylate is combined with Ibandronate.	Approved
Cilostazol	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Cilostazol.	Approved, Investigational
Cimicoxib	The risk or severity of gastrointestinal bleeding can be increased when Cimicoxib is combined with Ibandronate.	Investigational
Cinnarizine	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Cinnarizine.	Approved, Investigational
Cinoxacin	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Cinoxacin.	Approved, Investigational, Withdrawn
Ciprofibrate	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ibandronate is combined with Ciprofibrate.	Approved, Investigational
Ciprofloxacin	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Ciprofloxacin.	Approved, Investigational
Cisapride	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Cisapride.	Approved, Investigational, Withdrawn
Cisplatin	The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cisplatin is combined with Ibandronate.	Approved
Citalopram	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Citalopram.	Approved
Clarithromycin	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Clarithromycin.	Approved
Clemastine	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Clemastine.	Approved, Investigational
Clodronic Acid	The risk or severity of hypocalcemia can be increased when Clodronic Acid is combined with Ibandronate.	Approved, Investigational, Vet Approved
Clofibrate	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ibandronate is combined with Clofibrate.	Approved, Investigational
Clofibride	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ibandronate is combined with Clofibride.	Experimental
Clomipramine	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Clomipramine.	Approved, Investigational, Vet Approved
Clonixin	The risk or severity of gastrointestinal bleeding can be increased when Clonixin is combined with Ibandronate.	Approved
Clozapine	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Clozapine.	Approved
Cocaine	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Cocaine.	Approved, Illicit
Colistimethate	The risk or severity of nephrotoxicity and hypocalcemia can be increased when Colistimethate is combined with Ibandronate.	Approved, Vet Approved
Crizotinib	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Crizotinib.	Approved
CUDC-101	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with CUDC-101.	Investigational
CUDC-907	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with CUDC-907.	Investigational
Cyclizine	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Cyclizine.	Approved
Cyclosporine	The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cyclosporine is combined with Ibandronate.	Approved, Investigational, Vet Approved
Cyproheptadine	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Cyproheptadine.	Approved
Dabrafenib	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Dabrafenib.	Approved, Investigational
Dasatinib	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Dasatinib.	Approved, Investigational
Deferasirox	The risk or severity of gastrointestinal bleeding and gastrointestinal ulceration can be increased when Ibandronate is combined with Deferasirox.	Approved, Investigational
Degarelix	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Degarelix.	Approved
Delamanid	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Delamanid.	Approved, Investigational
Desflurane	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Desflurane.	Approved
Desipramine	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Desipramine.	Approved, Investigational
Desloratadine	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Desloratadine.	Approved, Investigational
Deutetrabenazine	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Deutetrabenazine.	Approved, Investigational
Dexbrompheniramine	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Dexbrompheniramine.	Approved
Dexchlorpheniramine	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Dexchlorpheniramine.	Experimental, Investigational
Dexchlorpheniramine maleate	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Dexchlorpheniramine maleate.	Approved
Dexibuprofen	The risk or severity of gastrointestinal bleeding can be increased when Dexibuprofen is combined with Ibandronate.	Approved, Investigational
Dexketoprofen	The risk or severity of gastrointestinal bleeding can be increased when Dexketoprofen is combined with Ibandronate.	Approved, Investigational
Dexlansoprazole	The therapeutic efficacy of Ibandronate can be decreased when used in combination with Dexlansoprazole.	Approved, Investigational
Dexrabeprazole	The therapeutic efficacy of Ibandronate can be decreased when used in combination with Dexrabeprazole.	Experimental
Dibekacin	The risk or severity of nephrotoxicity and hypocalcemia can be increased when Dibekacin is combined with Ibandronate.	Experimental
Diclofenac	The risk or severity of gastrointestinal bleeding can be increased when Diclofenac is combined with Ibandronate.	Approved, Vet Approved
Difenpiramide	The risk or severity of gastrointestinal bleeding can be increased when Difenpiramide is combined with Ibandronate.	Experimental
Difloxacin	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Difloxacin.	Vet Approved
Diflunisal	The risk or severity of gastrointestinal bleeding can be increased when Diflunisal is combined with Ibandronate.	Approved, Investigational
Dihydrostreptomycin	The risk or severity of nephrotoxicity and hypocalcemia can be increased when Dihydrostreptomycin is combined with Ibandronate.	Investigational, Vet Approved
Dimenhydrinate	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Dimenhydrinate.	Approved
Diphenhydramine	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Diphenhydramine.	Approved, Investigational
Disopyramide	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Disopyramide.	Approved
Dofetilide	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Dofetilide.	Approved, Investigational
Dolasetron	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Dolasetron.	Approved, Investigational
Domperidone	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Domperidone.	Approved, Investigational, Vet Approved
Donepezil	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Donepezil.	Approved
Dosulepin	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Dosulepin.	Approved
Doxepin	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Doxepin.	Approved, Investigational
Doxylamine	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Doxylamine.	Approved, Vet Approved
Dronedarone	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Dronedarone.	Approved
Droperidol	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Droperidol.	Approved, Vet Approved
Droxicam	The risk or severity of gastrointestinal bleeding can be increased when Droxicam is combined with Ibandronate.	Withdrawn
Ebastine	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Ebastine.	Approved, Investigational
Elcatonin	The risk or severity of hypocalcemia can be increased when Elcatonin is combined with Ibandronate.	Experimental
Eliglustat	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Eliglustat.	Approved
Emedastine	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Emedastine.	Approved
Endostatin	The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Endostatin is combined with Ibandronate.	Investigational
Enoxacin	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Enoxacin.	Approved, Investigational
Entinostat	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Entinostat.	Investigational
Epinastine	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Epinastine.	Approved, Investigational
Epirizole	The risk or severity of gastrointestinal bleeding can be increased when Epirizole is combined with Ibandronate.	Approved
Eribulin	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Eribulin.	Approved, Investigational
Erlotinib	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Erlotinib.	Approved, Investigational
Erythromycin	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Erythromycin.	Approved, Investigational, Vet Approved
Escitalopram	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Escitalopram.	Approved, Investigational
Esomeprazole	The therapeutic efficacy of Ibandronate can be decreased when used in combination with Esomeprazole.	Approved, Investigational
Etacrynic acid	The risk or severity of hypocalcemia can be increased when Etacrynic acid is combined with Ibandronate.	Approved, Investigational
Ethenzamide	The risk or severity of gastrointestinal bleeding can be increased when Ethenzamide is combined with Ibandronate.	Experimental
Etidronic acid	The risk or severity of hypocalcemia can be increased when Etidronic acid is combined with Ibandronate.	Approved
Etodolac	The risk or severity of gastrointestinal bleeding can be increased when Etodolac is combined with Ibandronate.	Approved, Investigational, Vet Approved
Etofenamate	The risk or severity of gastrointestinal bleeding can be increased when Etofenamate is combined with Ibandronate.	Approved, Investigational
Etofibrate	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ibandronate is combined with Etofibrate.	Approved
Etoricoxib	The risk or severity of gastrointestinal bleeding can be increased when Etoricoxib is combined with Ibandronate.	Approved, Investigational
Ezogabine	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Ezogabine.	Approved, Investigational
Famotidine	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Famotidine.	Approved
Felbamate	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Felbamate.	Approved
Felbinac	The risk or severity of gastrointestinal bleeding can be increased when Felbinac is combined with Ibandronate.	Experimental
Fenbufen	The risk or severity of gastrointestinal bleeding can be increased when Fenbufen is combined with Ibandronate.	Approved
Fenofibrate	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ibandronate is combined with Fenofibrate.	Approved
Fenofibric acid	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ibandronate is combined with Fenofibric acid.	Approved
Fenoprofen	The risk or severity of gastrointestinal bleeding can be increased when Fenoprofen is combined with Ibandronate.	Approved
Fentiazac	The risk or severity of gastrointestinal bleeding can be increased when Fentiazac is combined with Ibandronate.	Experimental
Feprazone	The risk or severity of gastrointestinal bleeding can be increased when Feprazone is combined with Ibandronate.	Experimental
Ferric ammonium citrate	Ferric ammonium citrate can cause a decrease in the absorption of Ibandronate resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved
Ferric cation	Ferric cation can cause a decrease in the absorption of Ibandronate resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved
Ferric hydroxide	Ferric hydroxide can cause a decrease in the absorption of Ibandronate resulting in a reduced serum concentration and potentially a decrease in efficacy.	Experimental
Ferric oxide	Ferric oxide can cause a decrease in the absorption of Ibandronate resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved
Ferric subsulfate	Ferric subsulfate can cause a decrease in the absorption of Ibandronate resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved, Experimental
Ferric sulfate	Ferric sulfate can cause a decrease in the absorption of Ibandronate resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved
Ferrous bisglycinate	Ferrous bisglycinate can cause a decrease in the absorption of Ibandronate resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved
Ferrous chloride	Ferrous chloride can cause a decrease in the absorption of Ibandronate resulting in a reduced serum concentration and potentially a decrease in efficacy.	Experimental
Ferrous fumarate	Ferrous fumarate can cause a decrease in the absorption of Ibandronate resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved
Ferrous gluconate	Ferrous gluconate can cause a decrease in the absorption of Ibandronate resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved
Ferrous succinate	Ferrous succinate can cause a decrease in the absorption of Ibandronate resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved
Ferrous sulfate	Ferrous sulfate can cause a decrease in the absorption of Ibandronate resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved, Experimental
Ferumoxides	Ferumoxides can cause a decrease in the absorption of Ibandronate resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved
Ferumoxsil	Ferumoxsil can cause a decrease in the absorption of Ibandronate resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved
Fexofenadine	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Fexofenadine.	Approved, Investigational
Fingolimod	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Fingolimod.	Approved, Investigational
Firocoxib	The risk or severity of gastrointestinal bleeding can be increased when Firocoxib is combined with Ibandronate.	Experimental, Vet Approved
Flecainide	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Flecainide.	Approved, Withdrawn
Fleroxacin	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Fleroxacin.	Approved
Floctafenine	The risk or severity of gastrointestinal bleeding can be increased when Floctafenine is combined with Ibandronate.	Approved, Withdrawn
Flomoxef	The risk or severity of nephrotoxicity and hypocalcemia can be increased when Flomoxef is combined with Ibandronate.	Investigational
Fluconazole	The risk or severity of QTc prolongation can be increased when Fluconazole is combined with Ibandronate.	Approved, Investigational
Flumequine	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Flumequine.	Withdrawn
Flunixin	The risk or severity of gastrointestinal bleeding can be increased when Flunixin is combined with Ibandronate.	Vet Approved
Flunoxaprofen	The risk or severity of gastrointestinal bleeding can be increased when Flunoxaprofen is combined with Ibandronate.	Experimental
Fluorouracil	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Fluorouracil.	Approved
Fluoxetine	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Fluoxetine.	Approved, Vet Approved
Flupentixol	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Flupentixol.	Approved, Investigational, Withdrawn
Flurbiprofen	The risk or severity of gastrointestinal bleeding can be increased when Flurbiprofen is combined with Ibandronate.	Approved, Investigational
Fluvastatin	The risk or severity of myopathy and rhabdomyolysis can be increased when Ibandronate is combined with Fluvastatin.	Approved
Formoterol	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Formoterol.	Approved, Investigational
Foscarnet	The risk or severity of nephrotoxicity and hypocalcemia can be increased when Foscarnet is combined with Ibandronate.	Approved
Framycetin	The risk or severity of nephrotoxicity and hypocalcemia can be increased when Framycetin is combined with Ibandronate.	Approved
Fumagillin	The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Fumagillin is combined with Ibandronate.	Experimental
Furosemide	The risk or severity of hypocalcemia can be increased when Furosemide is combined with Ibandronate.	Approved, Vet Approved
Gadobenic acid	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Gadobenic acid.	Approved, Investigational
Galantamine	The risk or severity of QTc prolongation can be increased when Galantamine is combined with Ibandronate.	Approved
Garenoxacin	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Garenoxacin.	Investigational
Gatifloxacin	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Gatifloxacin.	Approved, Investigational
Gemfibrozil	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ibandronate is combined with Gemfibrozil.	Approved
Gemifloxacin	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Gemifloxacin.	Approved, Investigational
Geneticin	The risk or severity of nephrotoxicity and hypocalcemia can be increased when Geneticin is combined with Ibandronate.	Experimental
Gentamicin	The risk or severity of nephrotoxicity and hypocalcemia can be increased when Gentamicin is combined with Ibandronate.	Approved, Vet Approved
GENTAMICIN C1A	The risk or severity of nephrotoxicity and hypocalcemia can be increased when GENTAMICIN C1A is combined with Ibandronate.	Experimental
Givinostat	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Givinostat.	Investigational
Gleptoferron	Gleptoferron can cause a decrease in the absorption of Ibandronate resulting in a reduced serum concentration and potentially a decrease in efficacy.	Vet Approved
Goserelin	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Goserelin.	Approved
Granisetron	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Granisetron.	Approved, Investigational
Grepafloxacin	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Grepafloxacin.	Approved, Investigational, Withdrawn
Guacetisal	The risk or severity of gastrointestinal bleeding can be increased when Guacetisal is combined with Ibandronate.	Experimental
Halofantrine	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Halofantrine.	Approved
Halofuginone	The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Halofuginone is combined with Ibandronate.	Investigational, Vet Approved
Haloperidol	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Haloperidol.	Approved
Histrelin	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Histrelin.	Approved
Human calcitonin	The risk or severity of hypocalcemia can be increased when Human calcitonin is combined with Ibandronate.	Approved, Investigational
Hydrolyzed Cephalothin	The risk or severity of nephrotoxicity and hypocalcemia can be increased when Hydrolyzed Cephalothin is combined with Ibandronate.	Experimental
Hydrotalcite	The serum concentration of Ibandronate can be decreased when it is combined with Hydrotalcite.	Approved, Experimental, Investigational
Hydroxychloroquine	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Hydroxychloroquine.	Approved
Hydroxyzine	The risk or severity of QTc prolongation can be increased when Hydroxyzine is combined with Ibandronate.	Approved
Hygromycin B	The risk or severity of nephrotoxicity and hypocalcemia can be increased when Hygromycin B is combined with Ibandronate.	Vet Approved
Ibuprofen	The risk or severity of gastrointestinal bleeding can be increased when Ibuprofen is combined with Ibandronate.	Approved
Ibuproxam	The risk or severity of gastrointestinal bleeding can be increased when Ibuproxam is combined with Ibandronate.	Withdrawn
Ibutilide	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Ibutilide.	Approved
Icosapent	The risk or severity of gastrointestinal bleeding can be increased when Icosapent is combined with Ibandronate.	Approved, Nutraceutical
Iloperidone	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Iloperidone.	Approved
Imatinib	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Imatinib.	Approved
Imidazole salicylate	The risk or severity of gastrointestinal bleeding can be increased when Imidazole salicylate is combined with Ibandronate.	Experimental
Imipramine	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Imipramine.	Approved
Incadronic acid	The risk or severity of hypocalcemia can be increased when Ibandronate is combined with Incadronic acid.	Approved, Investigational
Indacaterol	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Indacaterol.	Approved
Indapamide	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Indapamide.	Approved
Indobufen	The risk or severity of gastrointestinal bleeding can be increased when Indobufen is combined with Ibandronate.	Investigational
Indomethacin	The risk or severity of gastrointestinal bleeding can be increased when Indomethacin is combined with Ibandronate.	Approved, Investigational
Indoprofen	The risk or severity of gastrointestinal bleeding can be increased when Indoprofen is combined with Ibandronate.	Withdrawn
Iron isomaltoside 1000	Iron isomaltoside 1000 can cause a decrease in the absorption of Ibandronate resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved, Investigational
Iron saccharate	Iron saccharate can cause a decrease in the absorption of Ibandronate resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved
Isepamicin	The risk or severity of nephrotoxicity and hypocalcemia can be increased when Isepamicin is combined with Ibandronate.	Experimental
Isoflurane	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Isoflurane.	Approved, Vet Approved
Isoxicam	The risk or severity of gastrointestinal bleeding can be increased when Isoxicam is combined with Ibandronate.	Withdrawn
Isradipine	The risk or severity of QTc prolongation can be increased when Isradipine is combined with Ibandronate.	Approved, Investigational
Itraconazole	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Itraconazole.	Approved, Investigational
Ivabradine	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Ivabradine.	Approved
Ivosidenib	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Ivosidenib.	Approved, Investigational
Kanamycin	The risk or severity of nephrotoxicity and hypocalcemia can be increased when Kanamycin is combined with Ibandronate.	Approved, Investigational, Vet Approved
Kebuzone	The risk or severity of gastrointestinal bleeding can be increased when Kebuzone is combined with Ibandronate.	Experimental
Ketoconazole	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Ketoconazole.	Approved, Investigational
Ketoprofen	The risk or severity of gastrointestinal bleeding can be increased when Ketoprofen is combined with Ibandronate.	Approved, Vet Approved
Ketorolac	The risk or severity of gastrointestinal bleeding can be increased when Ketorolac is combined with Ibandronate.	Approved
Ketotifen	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Ketotifen.	Approved
Lansoprazole	The therapeutic efficacy of Ibandronate can be decreased when used in combination with Lansoprazole.	Approved, Investigational
Lapatinib	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Lapatinib.	Approved, Investigational
Latamoxef	The risk or severity of nephrotoxicity and hypocalcemia can be increased when Latamoxef is combined with Ibandronate.	Approved, Investigational
Lenalidomide	The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Lenalidomide is combined with Ibandronate.	Approved
Lenvatinib	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Lenvatinib.	Approved, Investigational
Leuprolide	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Leuprolide.	Approved, Investigational
Levocabastine	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Levocabastine.	Approved, Investigational
Levocetirizine	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Levocetirizine.	Approved
Levofloxacin	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Levofloxacin.	Approved, Investigational
Levomethadyl Acetate	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Levomethadyl Acetate.	Approved, Investigational
Lithium cation	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Lithium cation.	Experimental
Lomefloxacin	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Lomefloxacin.	Approved, Investigational
Lonazolac	The risk or severity of gastrointestinal bleeding can be increased when Lonazolac is combined with Ibandronate.	Experimental
Lopinavir	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Lopinavir.	Approved
Loracarbef	The risk or severity of nephrotoxicity and hypocalcemia can be increased when Loracarbef is combined with Ibandronate.	Investigational, Withdrawn
Loratadine	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Loratadine.	Approved, Investigational
Lornoxicam	The risk or severity of gastrointestinal bleeding can be increased when Lornoxicam is combined with Ibandronate.	Approved, Investigational
Lovastatin	The risk or severity of myopathy and rhabdomyolysis can be increased when Ibandronate is combined with Lovastatin.	Approved, Investigational
Loxoprofen	The risk or severity of gastrointestinal bleeding can be increased when Loxoprofen is combined with Ibandronate.	Approved, Investigational
Lumefantrine	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Lumefantrine.	Approved
Lumiracoxib	The risk or severity of gastrointestinal bleeding can be increased when Lumiracoxib is combined with Ibandronate.	Approved, Investigational
Macimorelin	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Macimorelin.	Approved, Investigational
Magaldrate	The serum concentration of Ibandronate can be decreased when it is combined with Magaldrate.	Approved, Withdrawn
Magnesium carbonate	The serum concentration of Ibandronate can be decreased when it is combined with Magnesium carbonate.	Approved, Investigational
Magnesium hydroxide	The serum concentration of Ibandronate can be decreased when it is combined with Magnesium hydroxide.	Approved, Investigational
Magnesium oxide	The serum concentration of Ibandronate can be decreased when it is combined with Magnesium oxide.	Approved
Magnesium peroxide	The serum concentration of Ibandronate can be decreased when it is combined with Magnesium peroxide.	Experimental
Magnesium salicylate	The risk or severity of gastrointestinal bleeding can be increased when Magnesium salicylate is combined with Ibandronate.	Approved
Magnesium silicate	The serum concentration of Ibandronate can be decreased when it is combined with Magnesium silicate.	Approved
Magnesium sulfate	The serum concentration of Ibandronate can be decreased when it is combined with Magnesium sulfate.	Approved, Investigational, Vet Approved
Magnesium Trisilicate	The serum concentration of Ibandronate can be decreased when it is combined with Magnesium Trisilicate.	Approved
Mannitol	The risk or severity of nephrotoxicity and hypocalcemia can be increased when Mannitol is combined with Ibandronate.	Approved, Investigational
Maprotiline	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Maprotiline.	Approved, Investigational
Meclofenamic acid	The risk or severity of gastrointestinal bleeding can be increased when Meclofenamic acid is combined with Ibandronate.	Approved, Vet Approved
Mefenamic acid	The risk or severity of gastrointestinal bleeding can be increased when Mefenamic acid is combined with Ibandronate.	Approved
Mefloquine	The risk or severity of QTc prolongation can be increased when Mefloquine is combined with Ibandronate.	Approved, Investigational
Meloxicam	The risk or severity of gastrointestinal bleeding can be increased when Meloxicam is combined with Ibandronate.	Approved, Vet Approved
Mepyramine	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Mepyramine.	Approved, Vet Approved
Mequitazine	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Mequitazine.	Approved
Mesalazine	The risk or severity of gastrointestinal bleeding can be increased when Mesalazine is combined with Ibandronate.	Approved
Mesoridazine	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Mesoridazine.	Approved, Investigational
Metamizole	The risk or severity of gastrointestinal bleeding can be increased when Metamizole is combined with Ibandronate.	Approved, Investigational, Withdrawn
Methadone	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Methadone.	Approved
Methotrimeprazine	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Methotrimeprazine.	Approved, Investigational
Metoclopramide	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Metoclopramide.	Approved, Investigational
Metronidazole	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Metronidazole.	Approved
Mevastatin	The risk or severity of myopathy and rhabdomyolysis can be increased when Ibandronate is combined with Mevastatin.	Experimental
Micronomicin	The risk or severity of nephrotoxicity and hypocalcemia can be increased when Micronomicin is combined with Ibandronate.	Experimental
Mifepristone	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Mifepristone.	Approved, Investigational
Mirabegron	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Mirabegron.	Approved
Mirtazapine	The risk or severity of QTc prolongation can be increased when Mirtazapine is combined with Ibandronate.	Approved
Mocetinostat	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Mocetinostat.	Investigational
Moexipril	The risk or severity of QTc prolongation can be increased when Moexipril is combined with Ibandronate.	Approved
Mofebutazone	The risk or severity of gastrointestinal bleeding can be increased when Mofebutazone is combined with Ibandronate.	Experimental
Morniflumate	The risk or severity of gastrointestinal bleeding can be increased when Morniflumate is combined with Ibandronate.	Approved
Moxifloxacin	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Moxifloxacin.	Approved, Investigational
Nabumetone	The risk or severity of gastrointestinal bleeding can be increased when Nabumetone is combined with Ibandronate.	Approved
Nalidixic Acid	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Nalidixic Acid.	Approved, Investigational
Naproxen	The risk or severity of gastrointestinal bleeding can be increased when Naproxen is combined with Ibandronate.	Approved, Vet Approved
Neamine	The risk or severity of nephrotoxicity and hypocalcemia can be increased when Neamine is combined with Ibandronate.	Experimental
Nelfinavir	The risk or severity of QTc prolongation can be increased when Nelfinavir is combined with Ibandronate.	Approved
Nemonoxacin	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Nemonoxacin.	Investigational
Neomycin	The risk or severity of nephrotoxicity and hypocalcemia can be increased when Neomycin is combined with Ibandronate.	Approved, Vet Approved
Nepafenac	The risk or severity of gastrointestinal bleeding can be increased when Nepafenac is combined with Ibandronate.	Approved, Investigational
Netilmicin	The risk or severity of nephrotoxicity and hypocalcemia can be increased when Netilmicin is combined with Ibandronate.	Approved, Investigational
Nicardipine	The risk or severity of QTc prolongation can be increased when Nicardipine is combined with Ibandronate.	Approved, Investigational
Nifenazone	The risk or severity of gastrointestinal bleeding can be increased when Nifenazone is combined with Ibandronate.	Experimental
Niflumic Acid	The risk or severity of gastrointestinal bleeding can be increased when Niflumic Acid is combined with Ibandronate.	Approved
Nilotinib	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Nilotinib.	Approved, Investigational
Nimesulide	The risk or severity of gastrointestinal bleeding can be increased when Nimesulide is combined with Ibandronate.	Approved, Investigational, Withdrawn
Nitroaspirin	The risk or severity of gastrointestinal bleeding can be increased when Nitroaspirin is combined with Ibandronate.	Investigational
Nitroprusside	Nitroprusside can cause a decrease in the absorption of Ibandronate resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved, Investigational
Norfloxacin	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Norfloxacin.	Approved
Nortriptyline	The risk or severity of QTc prolongation can be increased when Nortriptyline is combined with Ibandronate.	Approved
NS-398	The risk or severity of gastrointestinal bleeding can be increased when NS-398 is combined with Ibandronate.	Experimental
Octreotide	The risk or severity of QTc prolongation can be increased when Octreotide is combined with Ibandronate.	Approved, Investigational
Ofloxacin	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Ofloxacin.	Approved
Olanzapine	The risk or severity of QTc prolongation can be increased when Olanzapine is combined with Ibandronate.	Approved, Investigational
Olodaterol	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Olodaterol.	Approved
Olopatadine	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Olopatadine.	Approved
Olsalazine	The risk or severity of gastrointestinal bleeding can be increased when Olsalazine is combined with Ibandronate.	Approved
Omeprazole	The therapeutic efficacy of Ibandronate can be decreased when used in combination with Omeprazole.	Approved, Investigational, Vet Approved
Ondansetron	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Ondansetron.	Approved
Orbifloxacin	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Orbifloxacin.	Vet Approved
Orphenadrine	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Orphenadrine.	Approved
Oxaliplatin	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Oxaliplatin.	Approved, Investigational
Oxaprozin	The risk or severity of gastrointestinal bleeding can be increased when Oxaprozin is combined with Ibandronate.	Approved
Oxatomide	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Oxatomide.	Investigational
Oxolinic acid	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Oxolinic acid.	Experimental
Oxyphenbutazone	The risk or severity of gastrointestinal bleeding can be increased when Oxyphenbutazone is combined with Ibandronate.	Approved, Withdrawn
Oxytocin	The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Ibandronate.	Approved, Vet Approved
Paliperidone	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Paliperidone.	Approved
Pamidronate	The risk or severity of hypocalcemia can be increased when Pamidronate is combined with Ibandronate.	Approved
Panobinostat	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Panobinostat.	Approved, Investigational
Pantoprazole	The therapeutic efficacy of Ibandronate can be decreased when used in combination with Pantoprazole.	Approved
Papaverine	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Papaverine.	Approved, Investigational
Parecoxib	The risk or severity of gastrointestinal bleeding can be increased when Parecoxib is combined with Ibandronate.	Approved
Paromomycin	The risk or severity of nephrotoxicity and hypocalcemia can be increased when Paromomycin is combined with Ibandronate.	Approved, Investigational
Paroxetine	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Paroxetine.	Approved, Investigational
Pasireotide	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Pasireotide.	Approved
Pazopanib	The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Pazopanib is combined with Ibandronate.	Approved
Pazufloxacin	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Pazufloxacin.	Investigational
Pefloxacin	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Pefloxacin.	Approved
Pentamidine	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Pentamidine.	Approved, Investigational
Perflubutane	Perflubutane can cause a decrease in the absorption of Ibandronate resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved, Investigational
Perflutren	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Perflutren.	Approved
Pheniramine	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Pheniramine.	Approved
Phenylbutazone	The risk or severity of gastrointestinal bleeding can be increased when Phenylbutazone is combined with Ibandronate.	Approved, Vet Approved
Pimozide	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Pimozide.	Approved
Pipemidic acid	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Pipemidic acid.	Experimental
Piretanide	The risk or severity of hypocalcemia can be increased when Piretanide is combined with Ibandronate.	Approved
Piromidic acid	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Piromidic acid.	Experimental
Piroxicam	The risk or severity of gastrointestinal bleeding can be increased when Piroxicam is combined with Ibandronate.	Approved, Investigational
Pirprofen	The risk or severity of gastrointestinal bleeding can be increased when Pirprofen is combined with Ibandronate.	Experimental
Pitavastatin	The risk or severity of myopathy and rhabdomyolysis can be increased when Ibandronate is combined with Pitavastatin.	Approved
Pitolisant	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Pitolisant.	Approved, Investigational
Plazomicin	The risk or severity of nephrotoxicity and hypocalcemia can be increased when Plazomicin is combined with Ibandronate.	Approved, Investigational
Pomalidomide	The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Pomalidomide is combined with Ibandronate.	Approved
Posaconazole	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Posaconazole.	Approved, Investigational, Vet Approved
Pracinostat	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Pracinostat.	Investigational
Pranoprofen	The risk or severity of gastrointestinal bleeding can be increased when Pranoprofen is combined with Ibandronate.	Experimental, Investigational
Pravastatin	The risk or severity of myopathy and rhabdomyolysis can be increased when Ibandronate is combined with Pravastatin.	Approved
Primaquine	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Primaquine.	Approved
Probucol	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Probucol.	Approved, Investigational
Procainamide	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Procainamide.	Approved
Proglumetacin	The risk or severity of gastrointestinal bleeding can be increased when Proglumetacin is combined with Ibandronate.	Experimental
Promazine	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Promazine.	Approved, Vet Approved
Promethazine	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Promethazine.	Approved, Investigational
Propacetamol	The risk or severity of gastrointestinal bleeding can be increased when Propacetamol is combined with Ibandronate.	Approved, Investigational
Propafenone	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Propafenone.	Approved
Propofol	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Propofol.	Approved, Investigational, Vet Approved
Propyphenazone	The risk or severity of gastrointestinal bleeding can be increased when Propyphenazone is combined with Ibandronate.	Experimental
Proquazone	The risk or severity of gastrointestinal bleeding can be increased when Proquazone is combined with Ibandronate.	Experimental
Protriptyline	The risk or severity of QTc prolongation can be increased when Protriptyline is combined with Ibandronate.	Approved
Prulifloxacin	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Prulifloxacin.	Investigational
Prussian blue	Prussian blue can cause a decrease in the absorption of Ibandronate resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved
Puromycin	The risk or severity of nephrotoxicity and hypocalcemia can be increased when Puromycin is combined with Ibandronate.	Experimental
Quetiapine	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Quetiapine.	Approved
Quinidine	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Quinidine.	Approved, Investigational
Quinine	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Quinine.	Approved
Rabeprazole	The therapeutic efficacy of Ibandronate can be decreased when used in combination with Rabeprazole.	Approved, Investigational
Ranibizumab	The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Ranibizumab is combined with Ibandronate.	Approved
Ranolazine	The risk or severity of QTc prolongation can be increased when Ranolazine is combined with Ibandronate.	Approved, Investigational
Resveratrol	The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Resveratrol is combined with Ibandronate.	Approved, Experimental, Investigational
Ribociclib	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Ribociclib.	Approved, Investigational
Ribostamycin	The risk or severity of nephrotoxicity and hypocalcemia can be increased when Ribostamycin is combined with Ibandronate.	Approved, Investigational
Ricolinostat	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Ricolinostat.	Investigational
Rilpivirine	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Rilpivirine.	Approved
Risedronate	The risk or severity of hypocalcemia can be increased when Risedronate is combined with Ibandronate.	Approved, Investigational
Risperidone	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Risperidone.	Approved, Investigational
Ritonavir	The risk or severity of QTc prolongation can be increased when Ritonavir is combined with Ibandronate.	Approved, Investigational
Robenacoxib	The risk or severity of gastrointestinal bleeding can be increased when Robenacoxib is combined with Ibandronate.	Experimental, Vet Approved
Rofecoxib	The risk or severity of gastrointestinal bleeding can be increased when Rofecoxib is combined with Ibandronate.	Approved, Investigational, Withdrawn
Romidepsin	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Romidepsin.	Approved, Investigational
Ronifibrate	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ibandronate is combined with Ronifibrate.	Experimental
Roquinimex	The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Roquinimex is combined with Ibandronate.	Investigational
Rosoxacin	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Rosoxacin.	Approved, Investigational
Rosuvastatin	The risk or severity of myopathy and rhabdomyolysis can be increased when Ibandronate is combined with Rosuvastatin.	Approved
Roxithromycin	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Roxithromycin.	Approved, Investigational, Withdrawn
Rufloxacin	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Rufloxacin.	Experimental
Rupatadine	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Rupatadine.	Approved
Salbutamol	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Salbutamol.	Approved, Vet Approved
Salicylamide	The risk or severity of gastrointestinal bleeding can be increased when Salicylamide is combined with Ibandronate.	Approved
Salicylic acid	The risk or severity of gastrointestinal bleeding can be increased when Salicylic acid is combined with Ibandronate.	Approved, Investigational, Vet Approved
Salmeterol	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Salmeterol.	Approved
Salmon Calcitonin	The risk or severity of hypocalcemia can be increased when Salmon Calcitonin is combined with Ibandronate.	Approved, Investigational
Salsalate	The risk or severity of gastrointestinal bleeding can be increased when Salsalate is combined with Ibandronate.	Approved
Saquinavir	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Saquinavir.	Approved, Investigational
Sarafloxacin	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Sarafloxacin.	Vet Approved, Withdrawn
SC-236	The risk or severity of gastrointestinal bleeding can be increased when SC-236 is combined with Ibandronate.	Experimental, Investigational
Semaxanib	The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Semaxanib is combined with Ibandronate.	Investigational
Sertraline	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Sertraline.	Approved
Sevoflurane	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Sevoflurane.	Approved, Vet Approved
Simfibrate	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ibandronate is combined with Simfibrate.	Experimental
Simvastatin	The risk or severity of myopathy and rhabdomyolysis can be increased when Ibandronate is combined with Simvastatin.	Approved
Sisomicin	The risk or severity of nephrotoxicity and hypocalcemia can be increased when Sisomicin is combined with Ibandronate.	Investigational
Sitafloxacin	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Sitafloxacin.	Experimental, Investigational
Sodium bicarbonate	The serum concentration of Ibandronate can be decreased when it is combined with Sodium bicarbonate.	Approved
Sodium feredetate	Sodium feredetate can cause a decrease in the absorption of Ibandronate resulting in a reduced serum concentration and potentially a decrease in efficacy.	Experimental
Solifenacin	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Solifenacin.	Approved
Sorafenib	The risk or severity of QTc prolongation can be increased when Sorafenib is combined with Ibandronate.	Approved, Investigational
Sotalol	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Sotalol.	Approved
Sparfloxacin	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Sparfloxacin.	Approved, Investigational
Squalamine	The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Squalamine is combined with Ibandronate.	Investigational
Streptomycin	The risk or severity of nephrotoxicity and hypocalcemia can be increased when Streptomycin is combined with Ibandronate.	Approved, Vet Approved
Sulfamethoxazole	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Sulfamethoxazole.	Approved
Sulfasalazine	The risk or severity of gastrointestinal bleeding can be increased when Sulfasalazine is combined with Ibandronate.	Approved
Sulfisoxazole	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Sulfisoxazole.	Approved, Vet Approved
Sulindac	The risk or severity of gastrointestinal bleeding can be increased when Sulindac is combined with Ibandronate.	Approved, Investigational
Sulpiride	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Sulpiride.	Approved, Investigational
Sultopride	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Sultopride.	Experimental
Sunitinib	The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Sunitinib is combined with Ibandronate.	Approved, Investigational
Suprofen	The risk or severity of gastrointestinal bleeding can be increased when Suprofen is combined with Ibandronate.	Approved, Withdrawn
Suxibuzone	The risk or severity of gastrointestinal bleeding can be increased when Suxibuzone is combined with Ibandronate.	Experimental
Talniflumate	The risk or severity of gastrointestinal bleeding can be increased when Talniflumate is combined with Ibandronate.	Approved
Tamoxifen	The risk or severity of QTc prolongation can be increased when Tamoxifen is combined with Ibandronate.	Approved
Tandutinib	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Tandutinib.	Investigational
Technetium Tc-99m ciprofloxacin	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Technetium Tc-99m ciprofloxacin.	Investigational
Technetium Tc-99m oxidronate	The risk or severity of hypocalcemia can be increased when Ibandronate is combined with Technetium Tc-99m oxidronate.	Approved
Telavancin	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Telavancin.	Approved
Telithromycin	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Telithromycin.	Approved
Temafloxacin	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Temafloxacin.	Withdrawn
Tenidap	The risk or severity of gastrointestinal bleeding can be increased when Tenidap is combined with Ibandronate.	Experimental
Tenofovir	The risk or severity of nephrotoxicity and hypocalcemia can be increased when Tenofovir is combined with Ibandronate.	Experimental, Investigational
Tenofovir alafenamide	The risk or severity of nephrotoxicity and hypocalcemia can be increased when Tenofovir alafenamide is combined with Ibandronate.	Approved
Tenofovir disoproxil	The risk or severity of nephrotoxicity and hypocalcemia can be increased when Tenofovir disoproxil is combined with Ibandronate.	Approved, Investigational
Tenoxicam	The risk or severity of gastrointestinal bleeding can be increased when Tenoxicam is combined with Ibandronate.	Approved
Tepoxalin	The risk or severity of gastrointestinal bleeding can be increased when Tepoxalin is combined with Ibandronate.	Vet Approved
Terbutaline	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Terbutaline.	Approved
Terfenadine	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Terfenadine.	Approved, Withdrawn
Terlipressin	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Terlipressin.	Approved, Investigational
Terodiline	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Terodiline.	Experimental
Tetrabenazine	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Tetrabenazine.	Approved, Investigational
Tetraferric tricitrate decahydrate	Tetraferric tricitrate decahydrate can cause a decrease in the absorption of Ibandronate resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved
Thalidomide	The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Thalidomide is combined with Ibandronate.	Approved, Investigational, Withdrawn
Thioridazine	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Thioridazine.	Approved, Withdrawn
Thiothixene	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Thiothixene.	Approved
Tiaprofenic acid	The risk or severity of gastrointestinal bleeding can be increased when Tiaprofenic acid is combined with Ibandronate.	Approved
Tiludronic acid	The risk or severity of hypocalcemia can be increased when Ibandronate is combined with Tiludronic acid.	Approved, Investigational, Vet Approved
Tinoridine	The risk or severity of gastrointestinal bleeding can be increased when Tinoridine is combined with Ibandronate.	Investigational
Tizanidine	The risk or severity of QTc prolongation can be increased when Tizanidine is combined with Ibandronate.	Approved, Investigational
Tobramycin	The risk or severity of nephrotoxicity and hypocalcemia can be increased when Tobramycin is combined with Ibandronate.	Approved, Investigational
Tolfenamic Acid	The risk or severity of gastrointestinal bleeding can be increased when Tolfenamic Acid is combined with Ibandronate.	Approved, Investigational
Tolmetin	The risk or severity of gastrointestinal bleeding can be increased when Tolmetin is combined with Ibandronate.	Approved
Tolterodine	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Tolterodine.	Approved, Investigational
Torasemide	The risk or severity of hypocalcemia can be increased when Torasemide is combined with Ibandronate.	Approved
Toremifene	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Toremifene.	Approved, Investigational
Trazodone	The risk or severity of QTc prolongation can be increased when Trazodone is combined with Ibandronate.	Approved, Investigational
Trebananib	The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Trebananib is combined with Ibandronate.	Investigational
Treprostinil	The risk or severity of QTc prolongation can be increased when Treprostinil is combined with Ibandronate.	Approved, Investigational
Trimethoprim	The risk or severity of QTc prolongation can be increased when Trimethoprim is combined with Ibandronate.	Approved, Vet Approved
Trimipramine	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Trimipramine.	Approved
Triprolidine	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Triprolidine.	Approved
Triptorelin	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Triptorelin.	Approved, Vet Approved
Trolamine salicylate	The risk or severity of gastrointestinal bleeding can be increased when Trolamine salicylate is combined with Ibandronate.	Approved
Trovafloxacin	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Trovafloxacin.	Approved, Investigational, Withdrawn
Tucidinostat	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Tucidinostat.	Investigational
Valdecoxib	The risk or severity of gastrointestinal bleeding can be increased when Valdecoxib is combined with Ibandronate.	Approved, Investigational, Withdrawn
Valproic Acid	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Valproic Acid.	Approved, Investigational
Vancomycin	The risk or severity of nephrotoxicity and hypocalcemia can be increased when Vancomycin is combined with Ibandronate.	Approved
Vandetanib	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Vandetanib.	Approved
Vardenafil	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Vardenafil.	Approved
Vemurafenib	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Vemurafenib.	Approved
Venlafaxine	The risk or severity of QTc prolongation can be increased when Venlafaxine is combined with Ibandronate.	Approved
Vilanterol	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Vilanterol.	Approved
Voriconazole	The risk or severity of QTc prolongation can be increased when Voriconazole is combined with Ibandronate.	Approved, Investigational
Vorinostat	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Vorinostat.	Approved, Investigational
Zaltoprofen	The risk or severity of gastrointestinal bleeding can be increased when Zaltoprofen is combined with Ibandronate.	Approved, Investigational
Ziprasidone	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Ziprasidone.	Approved
Zoledronic acid	The risk or severity of hypocalcemia can be increased when Zoledronic acid is combined with Ibandronate.	Approved
Zomepirac	The risk or severity of gastrointestinal bleeding can be increased when Zomepirac is combined with Ibandronate.	Withdrawn
Zuclopenthixol	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Zuclopenthixol.	Approved, Investigational

Food Interactions

• Take on an empty stomach. All foods markedly reduce (up to 90%) ibandronate bioavailabilty. Take with plain water (not mineralized) at least 1 hour before any food. Bioavailability and effect on bone density are both impaired if the patient eats or drinks in less than 1 hour after taking this product. Drink a large glass of water and stay in an upright position for at least 60 minutes after taking this product.

References

Synthesis Reference

Revital Lifshitz-Liron, Thomas Bayer, Judith Aronhime, Michael Pinchasov, "Solid and crystalline ibandronate sodium and processes for preparation thereof." U.S. Patent US20070179119, issued August 02, 2007.

US20070179119

General References

1. Epstein S, Zaidi M: Biological properties and mechanism of action of ibandronate: application to the treatment of osteoporosis. Bone. 2005 Oct;37(4):433-40. [PubMed:16046205]

External Links

Human Metabolome Database

HMDB0014848

PubChem Compound

60852

PubChem Substance

46508134

ChemSpider

54839

BindingDB

12577

ChEMBL

CHEMBL997

Therapeutic Targets Database

DAP001022

PharmGKB

PA10270

HET

BFQ

RxList

RxList Drug Page

Drugs.com

Drugs.com Drug Page

Wikipedia

Ibandronate

ATC Codes

M05BA06 — Ibandronic acid

• M05BA — Bisphosphonates
• M05B — DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION
• M05 — DRUGS FOR TREATMENT OF BONE DISEASES
• M — MUSCULO-SKELETAL SYSTEM

PDB Entries

2f94 / 4umj

FDA label

Download (296 KB)

MSDS

Download (16 KB)

Clinical Trials

Clinical Trials

Phase	Status	Purpose	Conditions	Count
1	Completed	Not Available	Healthy Volunteers	1
1	Completed	Treatment	Healthy Volunteers	1
2	Completed	Treatment	Cancer, Breast	1
2	Completed	Treatment	Osteoporosis, Post-Menopausal	1
2	Completed	Treatment	Pain; Bone Neoplasms; Neoplasm Metastasis	1
2	Recruiting	Treatment	Bone destruction	1
2	Unknown Status	Treatment	Cancer, Breast	1
2	Withdrawn	Treatment	Bone Neoplasms / Neoplasms Metastasis / Pain	1
2, 3	Completed	Treatment	Bone destruction	1
2, 3	Unknown Status	Treatment	Transplant, Kidney	1
3	Active Not Recruiting	Treatment	Cancer, Breast	1
3	Completed	Supportive Care	Metastatic Cancers / Pain / Prostate Cancer	1
3	Completed	Treatment	Bone Marrow Edema of the Knee / Osteonecrosis of the Knee	1
3	Completed	Treatment	Cancer, Breast	1
3	Completed	Treatment	Haematological Malignancies	1
3	Completed	Treatment	Male Osteoporosis	1
3	Completed	Treatment	Osteoporosis, Post-Menopausal	1
3	Completed	Treatment	Pain; Bone Neoplasms; Neoplasm Metastasis	2
3	Completed	Treatment	Post Menopausal Osteoporosis	3
3	Completed	Treatment	Post-Menopausal Osteopenia	1
3	Completed	Treatment	Postmenopausal Osteoporosis (PMO)	2
3	Completed	Treatment	Postmenopausal Women With Osteoporosis	1
3	Completed	Treatment	Primary Osteoporosis	1
3	Completed	Treatment	Bone destruction	1
3	Terminated	Treatment	Aseptic / Aseptic Hip Necrosis / Hip Necrosis	1
3	Terminated	Treatment	Bone Neoplasms / Neoplasms Metastasis / Pain	2
3	Terminated	Treatment	Multiple Myeloma (MM)	1
3	Unknown Status	Treatment	Cancer, Breast / Hypercalcemia of Malignancy / Metastatic Cancers	1
3	Withdrawn	Supportive Care	Cancer, Breast / Hypercalcemia of Malignancy / Metastatic Cancers / Pain	1
4	Completed	Prevention	Bone destruction / Osteopenia / Rheumatoid Arthritis	1
4	Completed	Treatment	Osteoporosis, Post-Menopausal	3
4	Completed	Treatment	Pain; Bone Neoplasms; Neoplasm Metastasis	2
4	Completed	Treatment	Post Menopausal Osteoporosis	5
4	Completed	Treatment	Post-Menopausal Osteopenia	1
4	Completed	Treatment	Postmenopausal Osteoporosis (PMO)	8
4	Completed	Treatment	Systemic Lupus Erythematosus (SLE)	1
4	Completed	Treatment	Bone destruction	3
4	No Longer Available	Not Available	Postmenopausal Osteoporosis (PMO)	1
4	Suspended	Treatment	Human Immunodeficiency Virus (HIV) Infections	1
4	Terminated	Treatment	Lung Cancers	1
4	Terminated	Treatment	Bone destruction	1
Not Available	Completed	Not Available	Adenocarcinomas / Esophageal Cancers / Squamous Cell Carcinoma (SCC)	1
Not Available	Completed	Not Available	Postmenopausal Osteoporosis (PMO)	1
Not Available	Completed	Not Available	Bone destruction	3
Not Available	Enrolling by Invitation	Not Available	Atypical Femoral Fractures / Bisphosphonate Therapy / Bone destruction	1
Not Available	Withdrawn	Not Available	Cancer, Breast	1

Pharmacoeconomics

Manufacturers

• Hoffmann la roche inc

Packagers

• Diversified Healthcare Services Inc.
• F Hoffmann La Roche Ltd.
• F Hoffmann-La Roche Ltd.
• Physicians Total Care Inc.
• Vetter Pharma Fertigung GmbH and Co. KG

Dosage forms

Form	Route	Strength
Injection, solution	Intravenous	3 mg
Tablet, film coated	Oral	150 mg
Liquid	Intravenous	1 mg
Tablet, film coated	Oral	150 mg/1
Injection, solution, concentrate	Intravenous	1 mg
Injection, solution, concentrate	Intravenous	2 mg
Injection, solution, concentrate	Intravenous	6 mg
Tablet, film coated	Oral	50 mg
Injection	Intravenous	3 mg/3mL
Injection, solution	Intravenous	3 mg/3mL
Tablet	Oral	150 mg/1

Prices

Unit description	Cost	Unit
Boniva 3 mg/3ml Kit Box	524.22USD	box
Boniva 3 mg/3 ml syringe	504.06USD	syringe
Boniva 3 150 mg tablet Disp Pack	388.93USD	disp
Boniva 150 mg tablet	124.66USD	tablet
Boniva 2.5 mg tablet	4.16USD	tablet

DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.

Patents

Patent Number	Pediatric Extension	Approved	Expires (estimated)
US4927814	No	1995-03-17	2012-03-17
CA2346662	No	2006-05-09	2019-10-01
US7192938	Yes	2003-11-06	2023-11-06
US7718634	Yes	2003-11-06	2023-11-06
US7410957	No	2003-05-06	2023-05-06
US6294196	No	1999-10-07	2019-10-07
US6143326	No	1997-04-21	2017-04-21

Properties

State

Solid

Experimental Properties

Property	Value	Source
water solubility	Freely soluble	Not Available
logP	-2.1	Not Available

Predicted Properties

Property	Value	Source
Water Solubility	13.4 mg/mL	ALOGPS
logP	0.26	ALOGPS
logP	-2.5	ChemAxon
logS	-1.4	ALOGPS
pKa (Strongest Acidic)	0.66	ChemAxon
pKa (Strongest Basic)	9.93	ChemAxon
Physiological Charge	-1	ChemAxon
Hydrogen Acceptor Count	8	ChemAxon
Hydrogen Donor Count	5	ChemAxon
Polar Surface Area	138.53 Å2	ChemAxon
Rotatable Bond Count	9	ChemAxon
Refractivity	71.16 m3·mol-1	ChemAxon
Polarizability	29.51 Å3	ChemAxon
Number of Rings	0	ChemAxon
Bioavailability	1	ChemAxon
Rule of Five	Yes	ChemAxon
Ghose Filter	No	ChemAxon
Veber's Rule	No	ChemAxon
MDDR-like Rule	No	ChemAxon

Predicted ADMET features

Property	Value	Probability
Human Intestinal Absorption	-	0.9664
Blood Brain Barrier	-	0.5229
Caco-2 permeable	-	0.6012
P-glycoprotein substrate	Substrate	0.6888
P-glycoprotein inhibitor I	Non-inhibitor	0.8195
P-glycoprotein inhibitor II	Non-inhibitor	0.9838
Renal organic cation transporter	Non-inhibitor	0.9092
CYP450 2C9 substrate	Non-substrate	0.8376
CYP450 2D6 substrate	Non-substrate	0.7863
CYP450 3A4 substrate	Non-substrate	0.5504
CYP450 1A2 substrate	Non-inhibitor	0.832
CYP450 2C9 inhibitor	Non-inhibitor	0.8159
CYP450 2D6 inhibitor	Non-inhibitor	0.8987
CYP450 2C19 inhibitor	Non-inhibitor	0.8045
CYP450 3A4 inhibitor	Non-inhibitor	0.8901
CYP450 inhibitory promiscuity	Low CYP Inhibitory Promiscuity	0.9945
Ames test	Non AMES toxic	0.6527
Carcinogenicity	Non-carcinogens	0.683
Biodegradation	Not ready biodegradable	0.8346
Rat acute toxicity	2.4278 LD50, mol/kg	Not applicable
hERG inhibition (predictor I)	Weak inhibitor	0.6061
hERG inhibition (predictor II)	Non-inhibitor	0.6622

ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum	Spectrum Type	Splash Key
Predicted GC-MS Spectrum - GC-MS	Predicted GC-MS	Not Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)	Predicted LC-MS/MS	Not Available

Taxonomy

Description

This compound belongs to the class of organic compounds known as bisphosphonates. These are organic compounds containing two phosphonate groups linked together through a carbon atoms.

Kingdom

Organic compounds

Super Class

Organic acids and derivatives

Class

Organic phosphonic acids and derivatives

Sub Class

Bisphosphonates

Direct Parent

Bisphosphonates

Alternative Parents

Organic phosphonic acids / 1,3-aminoalcohols / Trialkylamines / Organopnictogen compounds / Organophosphorus compounds / Organooxygen compounds / Organic oxides / Hydrocarbon derivatives

Substituents

Bisphosphonate / Organophosphonic acid / 1,3-aminoalcohol / Tertiary aliphatic amine / Tertiary amine / Organic nitrogen compound / Organic oxygen compound / Organopnictogen compound / Organic oxide / Hydrocarbon derivative

Molecular Framework

Aliphatic acyclic compounds

External Descriptors

Not Available

Drug created on June 13, 2005 07:24 / Updated on August 02, 2018 07:39